Regenerative medicine market to reach $16.4 billion by 2026

3 December 2020
globaldata

Research from industry analyst GlobalData finds that the market for regenerative medicines will expand in the coming years to reach $16.4 billion in annual revenues.

The expansion over the forecast period to 2026 is driven largely by cell and gene therapies, with 53 such products currently available and a further 175 pipeline agents under development.

The gene therapy segment was valued at $734 million across the largest mature markets in 2019, and is forecast to reach $13.3 billion by 2026.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology